Generic Ambien Assaults Sanofi’s Top Line, But Lantus Growth Offsets Drop In Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Net sales fell 6 percent in the fourth quarter, but plummeting Ambien IR revenues are counteracted by 30 percent rise in insulin brand Lantus.